Anavex Life Sciences Corp (AVXL)

[falconer66a]

For Missling, short-term gains, or long-term wealth?

Although diehard investors on this board put utter and complete trust in the present CEO and the science,....

Well, as a diehard holder of several thousand AVXLs for almost a half-decade, let me tell where I put my trust.

First, the science. As a biologist familiar with cellular biology, I find the demonstrated and journal-documented science of the Anavex molecule’s mechanisms of action valid and profound; they will transform 21st-century medicine.

Then, Dr. Missling. Nope, the fellow simply does not lay out for the public each and every detail of what his management and research teams are doing. Given the remarkable science of the Anavex molecules, and the diseases they are targeting, it is so frustrating. I’m a science communicator; do a lot of science writing and make technical presentations to lay audiences (building on the skills I perfected as an advanced placement biology teacher). Herr Doktor Missling is never complete or thorough in what he tells about Anavex science.

But that’s not because English is his non-native second language. He’d say the same minimal stuff ins Deutsch (German). Frankly, he’s being coy. He’s already had one confrontation with lawyers trying for some sort of legal action resulting from something inadvertently stated. Never again, thankfully.

But, altogether, this is the ultimate and final consideration. Missling owns millions of dollars worth of Anavex shares, with warrants, etc. No individual has more to lose with an Anavex failure.

The converse is true. Hence, my faith in the man’s operation of the company. Missling is smart, has more advanced, diverse degrees than probably anyone posting on this message board. He knows exactly what he and his company are doing — and most significantly, what all of that will result in in a few years. Apparently, some believe Missling is playing, ever so awkwardly, his Anavex management game only while the getting is good. As the CEO, he’s getting paid handsomely, so until the company folds, he’ll do really fine. But, soon enough, it will eventually fail.

OR, he and his management and research teams are quietly arranging things so that when the FDA grants approval of blarcamesine, late this year or in 2023, Anavex Life Sciences Corp. will become a major, global pharmaceutical, requiring 9 zeros after the annual revenues integers (billions). Missling’s personal wealth will be in the billions.

So, which will it be? A few millions to Missling in the next two years, after which Anavex fails? Or, billions on out as Anavex science and drugs transform 21st-century medicine in the manner antibiotics did in the last century? Without complaining, I can quietly wait. In 2024 or 25, my few thousands of AVXLs will be worth only millions. Thank you, Dr. Missling.